Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> ASTRAZENECA Latest News

SEP 17, 2014 - Zacks Investment Research

A Must Read - Share

AstraZeneca's Constipation Drug Movantik Gets FDA Nod - Analyst Blog

AstraZeneca (AZN) announced that the FDA has cleared Movantik for use in adults with chronic non-cancer pain suffering from opioid-induced constipation.

Tags: AstraZeneca's Constipation Drug Movantik Gets FDA Nod - Analyst Blog,  Astrazeneca Latest News

SEP 16, 2014 - Zacks Investment Research

A Must Read - Share

AstraZeneca and Eli Lilly Collaborate for Alzheimer's Drug - Analyst Blog

AstraZeneca (AZN) has entered into an agreement with Eli Lilly and Company (LLY) for the development and commercialization of AZD3293.

Tags: AstraZeneca and Eli Lilly Collaborate for Alzheimer's Drug - Analyst Blog,  Astrazeneca Latest News

SEP 16, 2014 - Philadelphia Inquirer

A Must Read - Share

AstraZeneca gets up to $500 mln from Lilly for Alzheimer's drug

AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising - but risky - experimental Alzheimer's drug proves successful.

Tags: AstraZeneca gets up to $500 mln from Lilly for Alzheimer's drug,  Astrazeneca Latest News

SEP 16, 2014 - TheStreet

A Must Read - Share

How Will AstraZeneca (AZN) Stock React to FDA's Movantik Approval?

NEW YORK (TheStreet) -- Shares of AstraZenecaa dipped 0.18% to $73.65 in afternoon trading Tuesday despite the FDA's approval of the constipation drugaMovantik, developed by AstraZeneca andaNektar Therapeutics . The drug is an oral treatment for opioid-induced constipation in adults with chronic non-cancer pain. A common side effect of the opioid class of drugs is constipation, but Movantik, oranaloxegol,ais part ...

Tags: How Will AstraZeneca (AZN) Stock React to FDA's Movantik Approval?,  Astrazeneca Latest News

SEP 16, 2014 - Miami Herald

A Must Read - Share

Lilly, AstraZeneca team up on Alzheimer's drug

Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing.

Tags: Lilly, AstraZeneca team up on Alzheimer's drug,  Astrazeneca Latest News